News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Zenyth And MuriGen Collaborate On Inflammation Targets
February 20, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Zenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases. More...
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Australia
MORE ON THIS TOPIC
Artificial intelligence
Roche Makes Good on Dealmaking Promise With $1.1B Caris Cancer Collab
December 17, 2025
·
1 min read
·
Tristan Manalac
Startups
Addition Debuts With $100M to Advance One-Time Therapies for Rare, Chronic Diseases
December 17, 2025
·
1 min read
·
Tristan Manalac
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
December 16, 2025
·
3 min read
·
Annalee Armstrong
Venture capital
Ambros Launches With $125M To Bring Italian Non-Opioid Pain Drug to America
December 16, 2025
·
1 min read
·
Annalee Armstrong
